SV-IV Peptide 1–16 reduces coagulant power in normal Factor V and Factor V Leiden
2007

SV-IV Peptide 1–16 Reduces Coagulant Power in Factor V and Factor V Leiden

Sample size: 12 publication 10 minutes Evidence: moderate

Author Information

Author(s): Biagio Di Micco, Marilena Lepretti, Lidia Rota, Ilaria Quaglia, Paola Ferrazzi, Gianluca Di Micco, Pierpaolo Di Micco

Primary Institution: University of Sannio Benevento, Italy

Hypothesis

Can SV-IV Peptide 1–16 inhibit the procoagulant activity of normal Factor V or Factor V Leiden?

Conclusion

SV-IV Peptide 1–16 effectively reduces the coagulation capacity of both normal Factor V and Factor V Leiden in vitro.

Supporting Evidence

  • Peptide 1–16 significantly increased coagulation times in both normal and Leiden plasma.
  • The study demonstrated a more than 50% reduction in lysis of Chromozym X by Factor Xa when Peptide 1–16 was present.
  • Statistical analysis showed significant differences in coagulation times with p-values less than 0.001.

Takeaway

A special peptide can help slow down blood clotting in people with certain blood conditions.

Methodology

The study involved incubating SV-IV Peptide 1–16 with plasma samples from patients with Factor V Leiden and measuring coagulation times.

Potential Biases

Potential bias due to the small sample size and the specific patient population.

Limitations

The study used purified Factor V and did not have access to purified Factor V Leiden for testing.

Participant Demographics

Twelve patients, carriers of Factor V Leiden, with most having a history of thrombotic disease.

Statistical Information

P-Value

< 0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-5-69

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication